

Balaxi Pharmaceuticals Limited

Date: 24th August, 2026

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Subject: Re-appointment of Ms. Akshita Ostwal (DIN: 10026552) as an Independent Director of the Company.

Dear Sir/Madam,

Further to our letter dated 28th May, 2026, we write to advise that the Members of the Company at the 83rd Annual General Meeting held today i.e., 24th August, 2026, have approved the re-appointment of Ms. Akshita Ostwal (DIN: 10026552) as an Independent Director of the Company for a second term of five consecutive years with effect from September 05, 2026.

Brief profile and other details of Ms. Akshita Ostwal, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular dated 30th January, 2026, are given in the **Annexure - A.**

To the best of our knowledge & information, and as also confirmed by Ms. Akshita Ostwal, she has not been debarred from holding the office of Director by virtue of an order of the SEBI or any other authority.

The aforesaid information will also be available on the Company's website at www.balaxipharma.in

This is for your information and records.

Yours faithfully,
For Balaxi Pharmaceuticals Limited

Aman Purohit
(Company Secretary and Compliance Officer)
Membership No.: A59345

Encl: As above

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

ANNEXURE - A

Brief profile and other details of Ms. Akshita Ostwal, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular dated 30th January, 2026:

Sl. No.	Particulars	Remarks
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment of Ms. Akshita Ostwal as an Independent Director of the Company, for a second term of five consecutive years commencing from September 05, 2026 to September 04, 2031 (both days inclusive).
2.	Date of Appointment/ re-appointment/ cessation (as applicable) & term of appointment/ re-appointment	Date of re-appointment: September 05, 2026 Term of re-appointment: September 05, 2026 to September 04, 2031
3.	Brief Profile	Akshita Ostwal is the founder of Akshita Surana & Associates, a peer-reviewed firm of practicing company secretaries. With over ten years of experience in corporate laws and IPR laws advisory, consulting, and litigation, she has steadily built a reputation as a reliable and knowledgeable professional. Akshita is fellow practicing company secretary, a registered trademark agent, and she holds a Master's degree in Law. Additionally, she is also a member of the Chartered Governance Institute of UK & Ireland.
4.	Disclosure of relationship between the Directors (in case of appointment of a Director)	Not applicable
5.	Information as required under Circular No. NSE/CML/2018/02 dated June 20, 2018 issued by NSE.	Ms. Akshita Ostwal is not debarred from holding office of a Director by virtue of any SEBI order or any other such authority.

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in